Deutsch English Français

Contact

EP3904355

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP3904355

EP3904355 - SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF [Right-click to bookmark this link]
Status	The patent has been granted Status updated on 18.10.2024 Database last updated on 19.10.2024
Former	Grant of patent is intended Status updated on 10.06.2024
Former	Examination is in progress Status updated on 16.12.2022
Former	Request for examination was made Status updated on 01.10.2021
Former	The international publication has been made Status updated on 28.08.2020
Most recent event Tooltip	18.10.2024	(Expected) grant	published on 20.11.2024 [2024/47]
Applicant(s)	For all designated states Shenzhen TargetRx, Inc. Room 301 Unit 1 Building A Kexing Science Park No.15 of Keyuan Road Nanshan District Shenzhen, Guangdong 518057 / CN
	[2021/44]
Inventor(s)	01 / WANG, Yihan Room 301, Building A1 Kexing Science Park No.15 of Keyuan Road Nanshan District Shenzhen, Guangdong 518057 / CN
	02 / XING, Qingfeng Room 301, Building A1 Kexing Science Park No.15 of Keyuan Road Nanshan District Shenzhen, Guangdong 518057 / CN
	03 / AI, Yixin Room 301, Building A1 Kexing Science Park No.15 of Keyuan Road Nanshan District Shenzhen, Guangdong 518057 / CN
	[2024/47]
Former [2021/44]	01 / WANG, Yihan Shenzhen, Guangdong 518057 / CN
	02 / XING, Qingfeng Shenzhen, Guangdong 518057 / CN
	03 / AI, Yixin Shenzhen, Guangdong 518057 / CN
Representative(s)	Novitas Patent AB P.O. Box 55557 102 04 Stockholm / SE
	[2021/44]
Application number, filing date	20759406.0	13.02.2020
	[2021/44]
	WO2020CN74983
Priority number, date	CN201910127767	18.02.2019 Original published format: CN201910127767
	[2021/44]
Filing language	ZH
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2020168963
	Date:	27.08.2020
	Language:	ZH
	[2020/35]
	Type:	A1 Application with search report
	No.:	EP3904355
	Date:	03.11.2021
	Language:	EN
	[2021/44]
	Type:	B1 Patent specification
	No.:	EP3904355
	Date:	20.11.2024
	Language:	EN
	[2024/47]
Search report(s)	International search report - published on:	CN	27.08.2020
	(Supplementary) European search report - dispatched on:	EP	11.02.2022
Classification	IPC:	C07D487/04, C07D471/04, A61P35/00, A61K31/33	[2022/11]
	CPC:	C07D487/04 (EP,CN,US); A61P35/00 (EP,CN); A61P35/02 (EP,CN); C07D471/04 (EP,CN,US)
	Former IPC [2021/44]	C07D471/04, C07D401/04, C07D403/14, C07D403/04, C07D405/14, C07D413/14, C07D413/04, A61P35/00, A61K31/33
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/44]
Extension states	BA	Not yet paid
	ME	Not yet paid
Validation states	KH	Not yet paid
	MA	Not yet paid
	MD	Not yet paid
	TN	Not yet paid
Title	German:	SUBSTITUIERTE KONDENSIERTE AROMATISCHE RINGDERIVATE, ZUSAMMENSETZUNG UND DEREN VERWENDUNG	[2021/44]
	English:	SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF	[2021/44]
	French:	DÉRIVÉ DE CYCLE AROMATIQUE FUSIONNÉ SUBSTITUÉ, COMPOSITION ET UTILISATION DE CELUI-CI	[2021/44]
Entry into regional phase	29.07.2021	Translation filed
	29.07.2021	National basic fee paid
	29.07.2021	Search fee paid
	29.07.2021	Designation fee(s) paid
	29.07.2021	Examination fee paid
Examination procedure	29.07.2021	Examination requested [2021/44]
	31.08.2022	Amendment by applicant (claims and/or description)
	15.12.2022	Despatch of a communication from the examining division (Time limit: M04)
	14.04.2023	Reply to a communication from the examining division
	05.09.2023	Despatch of a communication from the examining division (Time limit: M04)
	04.01.2024	Reply to a communication from the examining division
	11.06.2024	Communication of intention to grant the patent
	09.10.2024	Fee for grant paid
	09.10.2024	Fee for publishing/printing paid
	09.10.2024	Receipt of the translation of the claim(s)
Fees paid	Renewal fee
	27.01.2022	Renewal fee patent year 03
	26.01.2023	Renewal fee patent year 04
	30.01.2024	Renewal fee patent year 05
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[X]WO2006091671 (LILLY CO ELI [US], et al) [X] 1-7,14,15 * examples 167,172,173,204,205,219,225,275,303,317; claims 1,16 *;
		[Y]WO2006108640 (NOVARTIS AG [CH], et al) [Y] 1-15 * claims 1,16 *;
		[Y]WO2015187818 (UNIV ARIZONA STATE [US]) [Y] 1-15 * claims 1,38,40, 44 *;
		[E]WO2021057877 (SHENZHEN TARGETRX INC [CN]) [E] 1-15* claims 1,13 *;
		[X] - CHEN YUEFENG ET AL, "Developing and applying a gene functional association network for anti-angiogenic kinase inhibitor activity assessment in an angiogenesis co-culture model", BMC GENOMICS, BIOMED CENTRAL LTD, LONDON, UK, (20080602), vol. 9, no. 1, ISSN 1471-2164, page 264, XP021033000 [X] 1-6,14,15 * figure 7B *
	International search	[X]EP1382603 (EISAI CO LTD [JP]) [X] 1, 2, 5-9, 17-20, 25 * description, embodiments 477-488, 499, 505, 507-513, 515-521, 639-641, 645, 649-660, 671, 678, 680-696, 702-706, 721, 728, 754, 755, 759, 760, 871-875, 1088 and 1092, and claims 15-31 *;
		[X]WO2004078756 (EISAI LONDON RES LAB LTD [GB], et al) [X] 1, 5-9 * description, page 30 *;
		[X]WO2007112093 (SYNTA PHARMACEUTICALS CORP [US], et al) [X] 1, 2, 5, 8, 9 * description, table 1 *;
		[X]CN101128461 (LILLY CO ELI [US]) [X] 1, 2, 4-25 * claims 18-20, and description, embodiment *;
		[A]CN102266341 (GUANGZHOU NO. 12 PEOPLE'S HOSPITAL) [A] 1-25 * entire document *;
		[A]CN104513252 (GUANGDONG HEC PHARMACEUTICAL) [A] 1-25* entire document *;
		[X]WO2018035061 (NEUPHARMA INC [US]) [X] 1-3, 7, 8 * description, paragraph [0451] *;
		[X]CN108948002 (UNIV XIAMEN) [X] 1-3, 5, 7, 8, 17-20, 25 * claims 11, 13 and 14 *;
		[X] - CHEN, Y. F. et al., "Developing and Applying a Gene Functional Association Network for Anti-angiogenic Kinase Inhibitor Activity Assessment in an Angiogenesis Co-culture Model", BMC Genomic, (20080602), vol. 9, doi:20200415173418X, XP021033000 [X] 1, 2, 4-8 * figure 7 *
		[X] - Anonymous, "- Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[2-fluoro-4-[7-[4-(1- piperazinylcarbonyl)phenyl]imidazo[1,2-a]pyridin-3-yl]phenyl]- (CA INDEX NAME)", REGISTRY, (20060922), Database accession no. 908329-69-1, URL: STN, XP055834256 [X] 1, 2, 4-10
		[PX] - Anonymous, "Benzamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(1,2,4-triazolo[4,3- a]pyrimidin-3-yl)- (CA INDEX NAME)", REGISTRY, (20190516), Database accession no. 2309151-24-2, URL: STN, XP055834271 [PX] 1, 2, 7, 8
	by applicant	US5376645
		- BERGE et al., "describe pharmaceutically acceptable salts in detail", J. Pharmaceutical Sciences, (19770000), vol. 66, pages 1 - 19
		- T. HIGUCHIV. STELLA, "Prodrugs as Novel Delivery Systems", A.C.S. Symposium Series, vol. 14
		- "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", D. FLEISHERS. RAMONH. BARBRA, Advanced Drug Delivery Reviews, (19960000), vol. 19, pages 115 - 130

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p